Data Use Policy
Effective: April 1, 2026 · Aimwell Bioceutical Systems, Inc.
1. Intelligence Data Sources
AimwellBio aggregates data from publicly available regulatory, clinical, and competitive intelligence sources. These include government databases (FDA, EMA, WHO, ClinicalTrials.gov), public patent registries (USPTO), public financial filings (SEC EDGAR), academic research repositories (PubMed, bioRxiv), and publicly available market signals. All source data is publicly accessible and does not include proprietary or confidential information from third parties.
2. How We Process Data
Raw signals from public sources are ingested, structured, classified, and enriched through our proprietary intelligence pipeline. This includes:
- Signal ingestion from 13 monitored sources on a continuous basis
- Natural language processing for entity extraction and classification
- Multi-model verification to ensure accuracy and reduce hallucination risk
- Confidence scoring and provenance tracing for every output claim
- Cross-signal correlation to identify patterns across disparate sources
No user-submitted data is used to train or improve models shared with other clients. Each organization’s intelligence context is private and isolated.
3. User-Generated Data
When you interact with the AimwellBio platform, certain data is generated and stored to improve your experience and deliver personalized intelligence. This includes:
- Entity watchlists and therapeutic area configurations
- Query history and interaction patterns (used to refine relevance)
- Feedback signals (corrections, dismissals, confirmations)
- Decision audit trails (for institutional memory and compliance)
This data belongs to your organization and is not shared, sold, or used for any purpose outside of delivering intelligence services to your account.
4. Data Retention
Intelligence outputs and user interaction data are retained for the duration of your active subscription plus 90 days. Upon account termination, you may request a full data export. All data is permanently deleted within 30 days of the retention period unless a legal hold applies.
5. Third-Party Data Sharing
AimwellBio does not sell, rent, or share your data with third parties for marketing or advertising purposes. Data may be shared only in the following limited circumstances:
- With infrastructure providers necessary to operate the platform (subject to strict data processing agreements)
- When required by law, regulation, or valid legal process
- To protect the rights, safety, or property of AimwellBio or its users
6. Security Measures
All data is encrypted in transit (TLS 1.2+) and at rest (AES-256). Access controls enforce role-based permissions. Infrastructure is hosted on SOC 2 compliant platforms. For enterprise and sovereign deployments, additional security configurations including dedicated tenancy and on-premise options are available.
7. FHIN Contributor Data
Healthcare professionals participating in the Federated Health Intelligence Network (FHIN) contribute anonymized, structured intelligence that enhances the collective signal quality across the network. FHIN contributions are stripped of personally identifiable information before aggregation. Contributors retain control over their participation level and may withdraw at any time.
8. Regulatory Compliance
AimwellBio’s data practices are designed to comply with applicable data protection regulations including GDPR, CCPA, and HIPAA (where applicable under BAA). For questions about data practices specific to your jurisdiction, contact privacy@aimwellbio.com.
9. Changes to This Policy
We may update this policy to reflect changes in our data practices or legal requirements. Material changes will be communicated via email to account holders and posted on this page with an updated effective date.
10. Contact
For questions about this Data Use Policy, contact:
Aimwell Bioceutical Systems, Inc.
privacy@aimwellbio.com